Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

IDO1 induces immune suppression in T cells through l-tryptophan (Trp) depletion and kynurenine (Kyn) accumulation in the local tumor microenvironment, suppressing effector T cells and hyperactivating regulatory T cells (Treg). Navoximod is an investigational small-molecule inhibitor of IDO1. This ph...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical cancer research Vol. 25; no. 11; p. 3220
Main Authors:	Jung, Kyung Hae, LoRusso, Patricia, Burris, Howard, Gordon, Michael, Bang, Yung-Jue, Hellmann, Matthew D, Cervantes, Andrés, Ochoa de Olza, Maria, Marabelle, Aurelien, Hodi, F Stephen, Ahn, Myung-Ju, Emens, Leisha A, Barlesi, Fabrice, Hamid, Omid, Calvo, Emiliano, McDermott, David, Soliman, Hatem, Rhee, Ina, Lin, Ray, Pourmohamad, Tony, Suchomel, Julia, Tsuhako, Amy, Morrissey, Kari, Mahrus, Sami, Morley, Roland, Pirzkall, Andrea, Davis, S Lindsey
Format:	Journal Article
Language:	English
Published:	United States 01.06.2019
Subjects:	Adult Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - pharmacokinetics Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use B7-H1 Antigen - antagonists & inhibitors Biomarkers, Tumor Humans Imidazoles - administration & dosage Imidazoles - pharmacokinetics Indoleamine-Pyrrole 2,3,-Dioxygenase - antagonists & inhibitors Indoles - administration & dosage Indoles - pharmacokinetics Magnetic Resonance Imaging Middle Aged Neoplasm Metastasis Neoplasm Staging Neoplasms - diagnosis Neoplasms - drug therapy Neoplasms - etiology Neoplasms - metabolism Tomography, X-Ray Computed Treatment Outcome
ISSN:	1557-3265, 1557-3265
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!